Hypoxia and tissue ischemia are the leading factors in the alteration of tissues in many
pathological conditions. Prevention and reversion of the effects of local ischemia, which …

Wound being one of the common clinical entities, often challenges the clinicians when
associated with non diabetic foot ulcer. Insulin, in addition to its hypoglycaemic activity is …

Introduction: Currently, much attention is paid to the pleiotropic effects of entretenimiento.
Purposes: Study of the protective effect exenatide and valdiation with pharmacological …

In recent years, new and effective therapeutic agents for blood glucose control have been
added to standard diabetes therapies: dipeptidyl peptidase-4 (DPP-4) inhibitors, which …

Objective: Diabetes mellitus (DM) is a spectrum of common metabolic disorders, arising from
a variety of pathogenic mechanisms. With an increasing incidence worldwide, DM will be …

Abstract Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are a well‐known and novel class of oral
antihyperglycaemic drugs. DPP‐4 inhibition facilitates ulcer healing in patients with …

Experimental evidence suggested that Exendin-4 (Exe4), an agonist at glucagon like
receptor-1 (GLP-1R), promoted tissue regeneration. We aimed to verify the effect of Exe4, in …

Background Random skin flaps are often used for plastic repair because they are
convenient and flexible. However, necrosis of flaps is a common complication that may lead …

Vildagliptin is a stable inhibitor of dipeptidyl peptidase-IV, a responsible enzyme that mainly
inactivates glucagon-like peptide-1, and now one of the widely used agents for the treatment …

Background Recently, glucagon-like peptide-1 (GLP-1)-based therapy, including dipeptidyl
peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists, has emerged as one of the …